FDA's "least burdensome" guidance disappoints industry
This article was originally published in Clinica
Device companies were surprised and disappointed to learn last week that the FDA's much-anticipated guidance covering the "least burdensome" path to win product approval will be more narrow in scope than had been envisaged.
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.